Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 50–65 years

Abstract

In patients aged 50-65 years undergoing AVR with the Carpentier-Edwards Perimount bioprosthesis, the expected valve durability was 19 years. Age was not a significant risk factor for SVD within this age group. Patient selection and attention to timing of reintervention may be determinants of long-term outcomes.

Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies

“…Of the 93 studies, 51 proved at overall low risk of bias. 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 Twenty one of the remaining 42 proved at overall moderate risk of bias 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 and 21 at overall high risk of bias. 90 91 92 93 94 95 …”

“…Twelve studies 21 22 25 26 27 33 53 68 69 81 85 90 with published Kaplan-Meier curves including 7603 patients reported on structural valve deterioration after SAVR. Supplementary appendix F presents the definition for structural valve deterioration across all 12 studies.…”

Long-Term Outcomes of the Mosaic Aortic Porcine Bioprosthesis in Japan ― Results From the Japan Mosaic Valve Long-Term Multicenter Study ―

“…The echocardiographic results were 641 cases of 1-year follow-up, 325 cases of 5-year follow-up, and 42 cases of 10-year follow-up for patients aged ≥65 years, and 79 cases of 1-year follow-up, 51 cases of 5-year follow-up, and 15 cases of 10-year follow-up for patients aged <65 years. The median (IQR) systolic pressure gradient was 17 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23) and 19 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25) The freedom from SVD at 12 years for the Mosaic valve was 93.5% for patients aged ≥65 years and 98.2% for patients aged <65 years in this study, similar to that observed with the St. Jude Medical Biocor valve (66.4% for patients aged ≤65 years; 87.1% for patients aged 65-75 years; and 90.8% for patients aged >75 years). 24 Similarly, for the Carpentier-Edwards pericardial valve, the freedom from SVD was 77.7% and 91.6% in patients aged 60-70 years and >70 years, respectively.…”

Transcatheter aortic valve replacement valve durability: Good enough for young, low-risk patients?

“…Age, lipid-lowering drugs, PPM, and high postoperative gradients were predictors of need for explant. Bourguignon and colleagues 25 followed 516 patients undergoing SAVR with Carpentier-Edwards Perimount bioprostheses aged 50 to 65 years between 1984 and 2008. Patients had an annual echocardiogram and clinical assessment by questionnaire.…”